Generics in Spain Research Report by Size, Growth, and Leading Players

HTF Market Intelligence released a new research report of 32 pages on title ‘Generics in Spain’  with detailed analysis, forecast and strategies.


Generics in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

– Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Spain

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Spain

– Leading company profiles reveal details of key generics market players’ global operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the Spain generics market with five year forecasts by both value and volume


Essential resource for top-line data and analysis covering the Spain generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Make an enquiry before buying this Report @

Reasons To Buy

– What was the size of the Spain generics market by value in 2016?

– What will be the size of the Spain generics market in 2021?

– What factors are affecting the strength of competition in the Spain generics market?

– How has the market performed over the last five years?

– How large is Spain’s generics market in relation to its regional counterparts?

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the ‘generic-eligible’ market, are not included.

The Spanish generics market is expected to generate total revenues of $3.1bn in 2016, representing a compound annual growth rate (CAGR) of 6.8% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 4.9% between 2012 and 2016, to reach a total of 81.2% of total pharma volume in 2016.

In Spain there is a great deal of difference in per capita public pharmaceutical expenditure. There is also a big difference in terms of prescriptions per capita. This is largely caused by differences in the age of its population in different areas. However, this gap is slowly closing.

Read Detailed Table of Content @

Executive Summary

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market volume

Market Segmentation

Geography segmentation

Market Outlook

Market value forecast

Market volume forecast

Five Forces Analysis


Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Esteve Group

Mylan Inc.

Sandoz International GmbH

Teva Pharmaceutical Industries Limited


Buy this report @

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

Ph: +1 (206) 317 1218